Sanchis Artero, LauraCortés Rizo, XavierMartínez Blanch, Juan FranciscoManresa Vera, SergioCortés Castell, ErnestoValls Gandia, MarinaIborra, MarisaProducción Científica UCH 2021UCH. Departamento de Medicina y Cirugía2022-05-042022-05-042021-05-11Sanchis-Artero, L., Martínez-Blanch, J.F., Manresa-Vera, S., Cortés-Castell, E., Valls-Gandia, M., Iborra, M. et al. (2021). Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment. Scientific Reports, vol. 11, art. 10016 (11 may.). DOI: https://doi.org/10.1038/s41598-021-88823-22045-2322 (Electrónico)http://hdl.handle.net/10637/13696Este artículo se encuentra disponible en la siguiente URL: https://www.nature.com/articles/s41598-021-88823-2.pdfEn este artículo también participan: Jose Maria Paredes-Arquiola, Maia Boscá-Watts, Jose Maria Huguet, Rafael Gil-Borrás y Josefa Rodríguez-Morales.Intestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects. This prospective multicenter observational study involved 27 CD patients initiating anti-TNF treatment and 16 healthy individuals. Inflammatory activity was determined at baseline, 3 and 6 months, classifying patients into responders and nonresponders. Fecal microbiota was analyzed by massive genomic sequencing thought 16S rRNA amplicon sequencing before and after six months of anti-TNF treatment. The CD cohort showed a decrease in genera of the class Clostridia, short-chain fatty acid producers, and an increase in the phylum Proteobacteria (p < 0.01) versus the healthy cohort. After anti-TNF treatment, the phylum Proteobacteria also increased in non-responders versus responders (13/27) (p < 0.005), with the class Clostridia increasing. In addition, alpha diversity increased in responders versus non-responders (p < 0.01), tending towards eubiosis. An association was found (p < 0.001) in the F.prausnitzii/E.coli ratio between responders and non-responders. The F/E ratio was the most accurate biomarker of anti-TNF response (area under the curve 0.87). Thus, anti-TNF treatment allows partial restoration of intestinal microbiota in responders and the F.prausnitzii/E.coli ratio can provide a reliable indicator of response to anti-TNF in CD.application/pdfenopen accessGastroenterología.Gastroenterology.Digestive organs - Diseases.Crohn's disease - Microbiology.Aparato digestivo - Enfermedades.Crohn, Enfermedad de - Microbiología.Artículohttps://doi.org/10.1038/s41598-021-88823-2https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es